A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Clinical trial NCT05272813 · TERMINATED

Trial details

NCT number: NCT05272813
Sponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2022-04-28
Primary completion: 2023-11-28
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.